MEK inhibitor resistance mechanisms and recent developments in combination trials
E Kun, YTM Tsang, CW Ng, DM Gershenson… - Cancer treatment …, 2021 - Elsevier
The mitogen-activated protein kinase (MAPK) pathway plays a vital role in cellular
processes such as gene expression, cell proliferation, cell survival, and apoptosis. Also …
processes such as gene expression, cell proliferation, cell survival, and apoptosis. Also …
Overcoming KRAS-Mutant Lung Cancer
More than 50 years after the discovery of RAS family proteins, which harbor the most
common activating mutations in cancer, the US Food and Drug Administration approved the …
common activating mutations in cancer, the US Food and Drug Administration approved the …
Identification of an energy metabolism‑related gene signature in ovarian cancer prognosis
L Wang, X Li - Oncology reports, 2020 - spandidos-publications.com
Abstract Changes in energy metabolism may be potential biomarkers and therapeutic
targets for cancer as they frequently occur within cancer cells. However, basic cancer …
targets for cancer as they frequently occur within cancer cells. However, basic cancer …
The anti-proliferative effect of PI3K/mTOR and ERK inhibition in monolayer and three-dimensional ovarian cancer cell models
E Dunn, K Chitcholtan, P Sykes, A Garrill - Cancers, 2022 - mdpi.com
Simple Summary In ovarian cancer patients the PI3K/AKT/mTOR and RAS/RAF/MEK/ERK
kinase signaling pathways are frequently dysregulated, making them potential targets of …
kinase signaling pathways are frequently dysregulated, making them potential targets of …
Concurrent inhibition of FAK/SRC and MEK overcomes MEK inhibitor resistance in Neurofibromatosis Type I related malignant peripheral nerve sheath tumors
Y Gu, C Wei, M Chung, H Li, Z Guo, M Long, Y Li… - Frontiers in …, 2022 - frontiersin.org
Malignant peripheral nerve sheath tumors (MPNST) are aggressive soft-tissue sarcomas
which lack effective drugs. Loss of the RAS GTPase-activating protein NF1 and subsequent …
which lack effective drugs. Loss of the RAS GTPase-activating protein NF1 and subsequent …
Tumor immune microenvironment in brain metastases from gynecologic malignancies
CM Gill, MR D'Andrea, S Tomita, J Suhner… - Cancer Immunology …, 2021 - Springer
Introduction The density and distribution of the tumor immune microenvironment associated
with brain metastases (BM) from gynecologic malignancies are unknown and have not been …
with brain metastases (BM) from gynecologic malignancies are unknown and have not been …
Should we abandon hormonal therapy in endometrial cancer? Outcomes of recurrent and metastatic endometrial cancer treated with systemic progestins
A Kulkarni, NMA Wright, AN Forget, T Ramsay… - Cancer …, 2023 - Wiley Online Library
Purpose The objective of this study is to determine primary survival endpoints in women with
recurrent and metastatic endometrial carcinoma (RMEC) treated with progestins. Methods A …
recurrent and metastatic endometrial carcinoma (RMEC) treated with progestins. Methods A …
MYC and HSF1 Cooperate to Drive PLK1 inhibitor Sensitivity in High Grade Serous Ovarian Cancer
I Williams, H DeHart, M O'Malley, B Walker… - bioRxiv, 2024 - biorxiv.org
Ovarian cancer is a deadly female cancer with high rates of recurrence. The primary
treatment strategy for patients is platinum-based therapy regimens that almost universally …
treatment strategy for patients is platinum-based therapy regimens that almost universally …